{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004982","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2026-07-29T12:15:16+00:00","discovered_at":"2026-07-29T12:20:00.352851+00:00","generated_at":"2026-07-29T12:23:32.792190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Filana Therapeutics Q2 2026 net loss $8.6M; cash $82.7M; clinical hold on TSC trial continues","bullets":["Net loss of $8.6M ($0.18 per share) vs $44.2M ($0.92) in Q2 2025; improvement due to no repeat of $31.25M litigation loss.","Cash and equivalents $82.7M at June 30, 2026, down from $95.5M at Dec 31, 2025; no debt.","R&D expenses $3.3M (down 35% YoY) as Alzheimer's program phased out; G&A $6.1M (down 85% YoY).","Paid $31.25M into escrow on July 23, 2026 for securities litigation settlement; cash restricted pending court approval.","Unrestricted cash at year-end 2026 expected $36-40M; second-half 2026 operating cash use $11-15M plus litigation funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004982","json":"https://secwatch.observer/filing/0001171843-26-004982.json","markdown":"https://secwatch.observer/filing/0001171843-26-004982.md","text":"https://secwatch.observer/filing/0001171843-26-004982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/0001171843-26-004982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/f8k_072826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T12:23:32.792190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}